X4 Pharmaceuticals (XFOR) Other financing activities (2018 - 2026)

X4 Pharmaceuticals (XFOR) has reported Other financing activities for 5 consecutive years, with $74000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities rose 60.87% year-over-year to $74000.0; the trailing twelve-month figure through Jun 2026 stood at $128000.0 (down 29.28% YoY), and the FY2025 full-year result was $98000.0, down 66.67% from the prior year.
• Other financing activities climbed to $74000.0 in Q2 2026 per XFOR's latest filing, from $2000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $135000.0 in Q4 2024 and bottomed at $2000.0 in Q1 2026.
• Historically, Other financing activities has averaged $61800.0 across 3 years, with a median of $52000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Other financing activities tumbled 61.48% in 2025, then surged 60.87% in 2026.
• Over 3 years, Other financing activities stood at $135000.0 in 2024, then sank by 61.48% to $52000.0 in 2025, then jumped by 42.31% to $74000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $74000.0, $2000.0, and $52000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.